PALO ALTO, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced that an interview with Dr. William (Wei) Cao, Chief Executive Officer for the Company, conducted by Stock News Now (SNN Incorporated) at last month's J.P. Morgan Healthcare Conference in San Francisco, is now available online.
The interview provides an overview of the Company's immune cell therapy platform focused on oncology and its Phase II clinical trial for Knee Osteoarthritis (KOA), which is differentiated by its use of the patient's own fat tissue. Also highlighted are the Company's impressive IP portfolio and its outlook for 2015 and 2016. "We look forward to acquiring more technology and partnerships in order to fortify our IP portfolio in 2015, and to announcing the interim results from our KOA Phase IIb clinical trial in the first quarter of 2015 and the full results from our KOA Phase IIb clinical trial in early 2016," said Dr. Cao.
About SNN Incorporated
SNN Incorporated is a global multimedia financial news and publishing company that focuses on market awareness and investor visibility for public and private micro-cap companies. The Company publishes StockNewsNow.com, MicroCap Review Magazine, and co-produces the Growth Capital Expo.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 firstname.lastname@example.org Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 email@example.com
Source:Cellular Biomedicine Group Inc.